Download MendeleyDevelopment of 3-arylaminothiophenic-2-carboxylic acid derivatives as new FTO inhibitors showing potent antileukemia activities.
Zhang, D., Liu, L., Li, M., Hu, X., Zhang, X., Xia, W., Wang, Z., Song, X., Huang, Y., Dong, Z., Yang, C.G.(2025) Eur J Med Chem 289: 117444-117444
- PubMed: 40022879 Search on PubMed
- DOI: https://doi.org/10.1016/j.ejmech.2025.117444
- Primary Citation Related Structures:
9KNI - PubMed Abstract:
Fat mass and obesity-associated protein (FTO) is the first discovered RNA N 6 -methyladenosine (m 6 A) demethylase. The highly expressed FTO protein is required to trigger oncogenic pathways in acute myeloid leukemia (AML), which makes FTO a promising antileukemia drug target. In this study, we identify 3-arylaminothiophenic-2-carboxylic acid derivatives as new FTO inhibitors with good antileukemia activity. We replaced the phenyl A-ring in FB23, the first-generation of FTO inhibitor, with five-membered heterocycles and synthesized a new class of FTO inhibitors. Compound 12o/F97 shows strong enzymatic inhibitory activity and potent antiproliferative activity. 12o/F97 selectively inhibits m 6 A demethylation by FTO rather than ALKBH5, and has minimal effect on m 1 A demethylation by ALKBH3. Additionally, 12o/F97 increases the protein levels of RARA and ASB2, while decreasing that of MYC in AML cell lines. Lastly, 12o/F97 exhibits antileukemia activity in a xenograft mice model without significant side-effects. The identification of 3-arylaminothiophenic-2-carboxylic acid derivatives as new FTO inhibitors not only expands the chemical space but also holds potential for antileukemia drug development.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
Organizational Affiliation:
